PMID: 16523387Mar 9, 2006Paper

Mecamylamine (Targacept)

IDrugs : the Investigational Drugs Journal
Abhay SinghMichael E Kelley

Abstract

Targacept Inc, under license from the University of South Florida, is developing a low-dose, liquid gel capsule formulation of the nicotinic acetylcholine antagonist mecamylamine, as a potential treatment for various neuropsychiatric disorders.

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Related Papers

Journal of Child and Adolescent Psychopharmacology
A A SilverP R Sanberg
Current Opinion in Investigational Drugs
Hugo Geerts
Current Opinion in Investigational Drugs
Orr Barak, Daniel S Loo
© 2021 Meta ULC. All rights reserved